Industries > Pharma > Global Next-Generation Antibody Therapies Market Forecast 2017-2027

Global Next-Generation Antibody Therapies Market Forecast 2017-2027

Antibody-Drug Conjugates (ADC), Biosimilar Antibodies, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments and Antibody-Like Proteins (ALPs)

PUBLISHED: 25 May 2017
PAGES: 249
PRODUCT CODE: PHA0195

Clear
WOOCS 2.2.1
DOWNLOAD FREE SAMPLE

The global next-generation antibody therapies market is expected to grow at a CAGR of 35.9% in the first half of the forecast period. The market is expected to grow at a CAGR of 22.4% from 2016-2027. The market is estimated at $3.1bn in 2016 and $14.1bn in 2021.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 249-page report you will receive 133 charts – all unavailable elsewhere.

The 249-page report provides clear detailed insight into the global next-generation antibody therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Next-Generation Antibody Therapies Market forecasts from 2017-2027

• Along with revenue prediction for the overall world market for next-generation antibody therapies, our investigation shows forecasts to 2027 for the following five submarkets:
– Antibody-drug conjugates (ADCs)
– Engineered antibodies
– Bispecific antibodies
– Antibody fragments and antibody-like proteins (ALPs)
– Biosimilar antibody therapies

• How will leading next-generation antibody therapies perform to 2027 at world level? Our study forecasts individual revenues of seven products:
– Adcetris
– Kadcyla
– Gazyva/Gazyvaro
– Poteligeo
– Removab
– Blincyto
– Kalbitor

• Our analyses show individual revenue forecasts to 2027 for these regional markets:
– US
– EU5 group
– Asia-Pacific region
– Latin America
– Rest of the World

Global Next-Generation Antibody Therapies Market Forecast 2017-2027

• This report discusses issues affecting the next-generation antibody therapies market:
– R&D for next generation antibodies – explore technologies and potentials
– Challenges with current monoclonal antibody (mAb) therapies
– Big pharma companies investing in next-generation antibody research and development
– Biosimilars and their effects on the next-generation antibody therapies market

• Our study discusses strengths, weaknesses, opportunities and threats as well as social, technological, economic and political factors that affect the next-generation antibody therapies market

Visiongain’s study is intended for anyone requiring commercial analyses for the next-generation antibody therapies market. You find data, trends and predictions.

Buy our report today Global Next-Generation Antibody Therapies Market Forecast 2017-2027: Antibody-Drug Conjugates (ADC), Biosimilar Antibodies, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments and Antibody-Like Proteins (ALPs).

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Next-Generation Antibody Therapies Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Next-Generation Antibody Therapies Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022

READ

Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022

READ

Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022

READ

Visiongain Publishes Medical Device Contract Manufacturing Market Report 2022-2032

The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.

13 September 2022

READ